Medical Treatments for Female Sexual Dysfunction: A Comprehensive Overview
Background
Female sexual dysfunction (FSD) encompasses a range of complex, overlapping sexual disorders with multifaceted causes, often rooted in a biopsychosocial framework. Healthcare providers frequently face challenges in effectively screening for and managing FSD, highlighting a critical need for clear guidance. This review synthesizes current medical treatments and outlines a multidisciplinary approach for addressing FSD across different life stages.
Results
The review identified flibanserin and bremelanotide as key psychoactive agents specifically indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women. For postmenopausal women experiencing HSDD, transdermal testosterone was highlighted as an effective and targeted hormonal intervention. The authors emphasized that a comprehensive approach to FSD requires more than just medication. Menopause hormone therapy (MHT), encompassing both systemic and local applications, was underscored as the primary and most crucial strategy for individualized management of sexual dysfunction in women transitioning through midlife. This multidisciplinary strategy, combining pharmacologic interventions with nonpharmacologic support, is essential to address the complex biological, psychological, and social factors contributing to FSD.
Why It Matters
This comprehensive review provides a vital resource for healthcare professionals, offering much-needed clarity on the diverse medical treatments available for Female Sexual Dysfunction (FSD). By clearly outlining specific pharmacologic agents tailored for different patient populations and emphasizing the necessity of a multidisciplinary approach, it aims to significantly improve patient care. This information can directly guide clinicians in developing more effective, individualized, and holistic treatment plans for women suffering from sexual dysfunction. Future research should focus on further refining diagnostic tools, exploring novel therapeutic targets, and conducting more head-to-head trials to expand and optimize treatment options.